HYDERGINE LC
LOE ApproachingNDAORALCAPSULE
Approved
Jan 1983
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
HYDERGINE LC is an oral capsule small-molecule NDA approved in 1983 by Novartis with unknown mechanism of action and indications. The product's specific therapeutic class and clinical applications are not documented in available data.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (30%); commercial teams likely focused on lifecycle management and transition planning rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings indicate minimal active hiring on HYDERGINE LC; roles available would focus on lifecycle management, competitive defense, and transition planning as the product approaches LOE. Career growth on this asset is limited compared to growth-stage or launch-stage products.
Brand ManagerField Sales Representative
Worked on HYDERGINE LC at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.